Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

MAP7D2 reduces CD8+ cytotoxic T lymphocyte infiltration through MYH9-HMGB1 axis in colorectal cancer

8 Sept 2022

Abstract excerpt

Immune checkpoint inhibitors (ICIs) represent a new paradigm in cancer immunotherapy, but can be largely restricted by the limited presence of CD8 + cytotoxic T lymphocytes (CTLs) in colorectal cancer (CRC) patients with microsatellite stable (MSS) tumors. Here, through next-generation sequencing, we identify microtubule-associated protein 7 domain 2 (MAP7D2) as an exploitable therapeutic maneuver to improve the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Immunotherapy and Biomarkers
Share to Immune Cell Function and Interaction
Share to Immunotherapy and Immune Responses

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 36081350
DOI: 10.1016/j.ymthe.2022.09.001

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

MAP7D2 reduces CD8+ cytotoxic T lymphocyte infiltration through MYH9-HMGB1 axis in colorectal cancerPMID 36081350Read ↗

The prognostic index of m7G-related genes in CRC correlates with immune infiltrationSemantic proximity Read ↗

B7H4 Expression Is More Frequent in MSS Status Colorectal Cancer and Is Negatively Associated with Tumour Infiltrating LymphocytesSemantic proximity Read ↗

Could microtubule inhibitors be the best choice of therapy in gastric cancer with high immune activity: mutant DYNC1H1 as a biomarker.Semantic proximity Read ↗

Overexpression and Role of HHLA2, a Novel Immune Checkpoint, in Colorectal CancerSemantic proximity Read ↗

To kill a cancer: Targeting the immune inhibitory checkpoint molecule, B7-H3Semantic proximity Read ↗

Expression Profile, Prognostic Value, and Therapeutic Potential of NSD2 in Pan-Cancer: A Systematic Analysis Integrating Multi-Omics DataSemantic proximity Read ↗

PTCH1 mutation promotes antitumor immunity and the response to immune checkpoint inhibitors in colorectal cancer patients.Semantic proximity Read ↗

Prognostic, Immunological, and Mutational Analysis of MTA2 in Pan-Cancer and Drug Screening for Hepatocellular CarcinomaSemantic proximity Read ↗

IDO1 inhibitor enhances the effectiveness of PD-1 blockade in microsatellite stable colorectal cancer by promoting macrophage pro-inflammatory phenotype polarization.Semantic proximity Read ↗

Emerging roles for HMGA2 in colorectal cancerSemantic proximity Read ↗

HMGA2 facilitates colorectal cancer progression via STAT3-mediated tumor-associated macrophage recruitmentSemantic proximity Read ↗

<i>MLL4/KMT2D</i> mutations increase immune activity and predict therapy efficacy in colorectal cancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.